← Back to All US Stocks

Kamada Ltd. (KMDA) Fundamental Analysis & AI Grade 2026

KMDA Nasdaq Pharmaceutical Preparations L3 CIK: 0001567529
Recently Updated • Analysis: May 28, 2026 • SEC Data: 2026-05-28

Kamada Ltd. (KMDA) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

KMDA Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

KMDA vs Healthcare Sector: How Kamada Ltd. Compares

How Kamada Ltd. compares to Healthcare sector averages

Net Margin
KMDA 0.0%
vs
Sector Avg 12.0%
KMDA Sector
ROE
KMDA 0.0%
vs
Sector Avg 15.0%
KMDA Sector
Current Ratio
KMDA 0.0x
vs
Sector Avg 2.0x
KMDA Sector
Debt/Equity
KMDA 0.0x
vs
Sector Avg 0.6x
KMDA Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Kamada Ltd. Stock Overvalued? KMDA Valuation Analysis 2026

Based on fundamental analysis, Kamada Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Kamada Ltd. Balance Sheet: KMDA Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

KMDA Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

KMDA SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Kamada Ltd. (CIK: 0001567529)

📋 Recent SEC Filings

Date Form Document Action
Apr 9, 2026 4 xslF345X06/ownership.xml View →
Apr 9, 2026 4 xslF345X06/ownership.xml View →
Apr 9, 2026 4 xslF345X06/ownership.xml View →
Apr 9, 2026 4 xslF345X06/ownership.xml View →
Apr 9, 2026 4 xslF345X06/ownership.xml View →

Frequently Asked Questions about KMDA

What is the AI rating for KMDA?

Kamada Ltd. (KMDA) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.

What are KMDA's key strengths?

Claude: Analysis in progress.

What are the risks of investing in KMDA?

Claude: Analysis in progress.

What is KMDA's revenue and growth?

Kamada Ltd. reported revenue of N/A.

Does KMDA pay dividends?

Kamada Ltd. does not currently pay dividends.

Where can I find KMDA SEC filings?

Official SEC filings for Kamada Ltd. (CIK: 0001567529) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is KMDA's EPS?

Kamada Ltd. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is KMDA's fundamental grade?

Based on our AI fundamental analysis in May 2026, Kamada Ltd. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is KMDA stock overvalued or undervalued?

Valuation metrics for KMDA: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is KMDA's AI grade for 2026?

Our dual AI analysis gives Kamada Ltd. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is KMDA's free cash flow?

Kamada Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.

How does KMDA compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 28, 2026 | Data as of: 2026-05-28 | Powered by Claude AI